CMS’s (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions
CMS’s (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions

SHENZHEN, CHINA, June 8, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that the preclinical results of its self-developed innovative INHBE-targeting small nucleic acid drug CMS-D008 injection ("CMS-D008"), have been presented in a poster at the American Diabetes Association (ADA) 86th Scientific Sessions (June 5-8, 2026, New Orleans, USA). As the world's largest and most authoritative annual scientific meeting in the fields of diabetes and metabolic diseases, it convened over 12,000 leading clinicians, researchers, and healthcare professionals worldwide to explore cutting-edge advances in diagnostics, therapies, and technologies.About CMS-D008CMS-D008 is a self-developed novel siRNA therapy administered by subcutaneous injection. It targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of INHBE-encoded Activin E protein, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. It demonstrates the potential for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. Currently, the Phase I clinical trial of CMS-D008 in healthy subjects is progressing steadily. In the future, it may be developed for the treatment of abdominal obesity and related metabolic diseases.CMS-D008 has demonstrated encouraging preclinical data. The preclinical research results of CMS-D008 presented at the ADA Scientific Sessions showed that in obese animal models, CMS-D008 efficiently and sustainably suppressed INHBE expression, achieving significant weight loss and fat reduction while sparing muscle mass, with a favorable safety profile, indicating the potential for healthy weight loss. Details are as follows:Title: CMS-D008 specifically silences INHBE mRNA, delivering fat-selective weight loss in preclinical studyPresentation Number: 3079-LBPresentation format: PosterDate/Time: June 7, 2026 01:30 PM - 02:30 PM (Local Time)Location: Hall D-EResults:In a high-fat diet-induced model of humanized INHBE obese mouse (hINHBE DIO mouse), CMS-D008 significantly reduced hepatic INHBE mRNA expression and serum Activin E protein levels, leading to marked decreases in body weight, total body fat, and regional fat mass while preserving lean mass.In a model of obese cynomolgus macaque, CMS-D008 also significantly reduced hepatic INHBE mRNA expression and plasma Activin E protein levels, and effectively suppressed weight gain induced by a sustained high-fat diet.The inclusion of these findings at the ADA Scientific Sessions reflects the international academic community's interest in the scientific value and clinical potential of CMS-D008 in the field of obesity/metabolic treatment. CMS-D008 will synergize with CMS-D005, a self-developed, clinical-stage innovative drug (a GLP-1R/GCGR dual agonist), to deliver highly effective weight-loss benefits and long-term maintenance of results, providing patients with a more comprehensive and innovative treatment option.CMS is committed to in-house R&D as a core driver of its long-term growth and continues to advance innovation in cutting-edge therapeutic areas. Currently, 6 self-developed products with global rights, including CMS-D008, have entered the clinical stage, with over 20 additional self-developed projects steadily progressing in preclinical research. Looking ahead, the Group will continue to focus on unmet medical needs, efficiently advance product R&D and commercialization, and bring more comprehensive and innovative therapies to benefit broad patient population.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

brooke
云顶新耀宣布与箕星药业达成LNZ100大中华区资产收购协议 强化眼科领域产品布局
云顶新耀宣布与箕星药业达成LNZ100大中华区资产收购协议 强化眼科领域产品布局

香港, 2026年6月8日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（HKEX 1952.HK）宣布与箕星药业（以下简称"箕星"）达成资产收购协议 (The Asset Purchase Agreement)，获得LNZ100（1.44% 醋克利定，美国商品名VIZZ）在大中华区（包含中国大陆，中国香港，中国澳门和中国台湾地区）的开发、生产与商业化权益。根据协议，云顶新耀将向箕星药业支付首付款以及开发里程碑付款。作为本协议的一部分，云顶新耀将获得箕星药业于2022年4月签订的许可协议及相关附属协议项下的权利、权益、主张、职责、义务及责任。此次交易将进一步丰富公司的创新产品组合，强化云顶新耀在眼科领域的布局，并提升战略协同效应。LNZ100是一款每日滴用一次、用于治疗老视的滴眼液，其主要成分醋克利定是一种小分子毒蕈碱型乙酰胆碱能受体（mAChR）激动剂，可引起瞳孔缩小，从而产生改善近视力的针孔效应。研究表明醋克利定的作用机制非常理想，基于其独特的高选择性瞳孔作用机制，既可以产生理想的缩瞳效应，又避免了近视漂移，因此具有针对最广泛患者群体的应用潜力。据公开资料显示，LNZ100已于2025年7月在美国获批，并于同年10月实现商业化上市；在中国，LNZ100已于2025年9月递交新药上市申请，预计2027年第一季度获批，有望填补国内治疗空白，成为针对老视的潜在同类最佳无创治疗方案。云顶新耀董事会主席吴以芳表示："此次收购LNZ100是公司持续深化眼科领域战略布局的重要一步。LNZ100作为一款兼具差异化优势和广阔市场前景的创新产品，在老视治疗领域具有明确的临床价值与应用潜力。随着人口结构变化，老视患者群体不断扩大，而无创治疗仍存在显著未满足的需求。LNZ100有望为老视患者提供全新的治疗选择，并进一步丰富眼科创新治疗方案。 LNZ100已在美国获批上市，目前正在中国加快推进新药上市审评进程。未来，我们将加快LNZ100的开发和上市，推动这一创新疗法尽早惠及更多老视患者。"箕星药业董事会执行董事兼首席执行官牟艳萍表示："我们相信云顶新耀凭借其卓越的商业化能力，将加速推进LNZ100的市场可及性，惠及更多中国老视患者。此次交易之后，箕星的产品管线全部聚焦心血管及代谢疾病治疗领域，该交易所获资金将助力箕星加速推进创新管线的全球临床开发。"老视，俗称"老花眼"，是指随着年龄增长，看近处物体逐渐模糊的生理现象。其原因在于眼部晶状体逐渐硬化、弹性减弱，导致调节功能下降，无法将近处物体的像聚焦在视网膜上，从而导致近视力下降。老视是随年龄增长常见的生理变化，研究显示，中国人群老视的平均发病年龄约为38岁，而到52岁时，发病率接近100%。目前，老视的治疗手段非常有限。佩戴眼镜需要频繁摘戴，给工作和生活带来诸多不便；手术作为侵入性、不可逆的有创操作，接受程度也十分有限。在非侵入性、安全有效且可逆的药物治疗方面，老视领域存在巨大的未满足医疗需求。此次LNZ100获中国NMPA新药上市申请受理是基于中国III期临床研究所取得的数据结果。该研究是一项多中心、随机、双盲、安慰剂对照的3期临床试验，由4周疗效试验和总计6个月的安全性试验组成，共招募了300名受试者，旨在观察LNZ100改善中国老视人群近视力并确证其疗效与安全性。研究结果显示，LNZ100达到了主要终点和关键次要终点，最佳远矫正下的近视力 （BCDVA）有三行或更佳的显著改善，并保持其最佳远视力（即视力下降不可超过5个字母）。研究结果还显示（所有p值均小于0.0001），LNZ100起效迅速，分别有84%和69%的受试者在用药后30分钟即获得两行及三行字母或更佳的近视力改善。且LNZ100药效持久，分别有61%和30%的受试者在用药后10 小时仍保持两行及三行字母或更佳的近视力改善。此外，LNZ100也具备出色的安全性，耐受性良好，在试验中没有发现与治疗相关的严重不良事件。近年来，云顶新耀已建立经过验证的以"科学及商业洞察驱动的准入、医学、市场、销售一体化协同（A2MS）"为核心的创新药商业化运营平台。随着多个创新产品陆续进入商业化阶段，公司商业化平台的规模效应和协同效应正持续释放。在此背景下，引入具备明确临床价值和市场潜力的后期资产，成为公司丰富产品组合、拓展增长空间的重要举措。此次获得LNZ100大中华区权益，将进一步强化云顶新耀眼科领域布局，并与现有商业化体系形成协同，持续提升创新资产的商业化价值。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ashley
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China, Strengthen Presence in Ophthalmology
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China, Strengthen Presence in Ophthalmology

HONG KONG, Jun 8, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals (“CORXEL”). Under the agreement, Everest has acquired the rights to develop, manufacture, and commercialize LNZ100 (1.44% aceclidine, U.S. brand name VIZZ) in Greater China, including Chinese mainland, Hong Kong SAR, Macao SAR, and Taiwan region. Everest will pay an upfront payment and potential development milestone payments. As part of this agreement, Everest will be assigned and transferred the rights and obligations under the LENZ License Agreement entered into by CORXEL in April 2022 and certain related ancillary agreements. This transaction is expected to further expand the Company’s innovative product portfolio, strengthen its presence in ophthalmology, and enhance overall strategic synergies across its business.LNZ100 is a once-daily prescription eye drop indicated for the treatment of presbyopia. Its active ingredient, aceclidine, is a small molecule acetylcholine receptor agonist that causes pupil contraction, or miosis, creating a pinhole effect that improves near vision. Studies have shown that aceclidine's mechanism of action (MOA) is well positioned to create a pinhole pupil effect while avoiding the impairment of distance vision called myopic shift. Aceclidine's unique pupil selective MOA, in which miosis is decoupled from myopic shift, is expected to allow it to target a broad patient population.According to publicly available information, LNZ100 received approval in the United States in July 2025 and was commercially launched in October of the same year. In China, the New Drug Application (NDA) for LNZ100 was submitted in September 2025, with approval expected in the first quarter of 2027. The therapy has the potential to address a significant unmet medical need in China and position itself as a best-in-class, non-invasive treatment option for presbyopia.“The acquisition of LNZ100 represents an important step in advancing Everest’s strategic focus in ophthalmology. LNZ100 is a differentiated asset with meaningful clinical value and strong commercial potential in the treatment of presbyopia,” said Yifang Wu, Chairman of the Board of Everest Medicines. “As the presbyopia patient population continues to grow, significant unmet needs remain in non-invasive treatment options. We believe LNZ100 has the potential to offer patients a novel, non-invasive therapeutic option and to further broaden the landscape of innovative ophthalmic treatments. The product has already been approved in the United States and is currently under regulatory review in China. We will continue to advance its development and commercialization to make this therapy accessible to presbyopia patients.”Ms. Sandy Mou, Board Executive Director and Chief Executive Officer of CORXEL, said: “We are confident that Everest Medicines’ strong commercialization capabilities will accelerate LNZ100’s market access and bring this innovative treatment to more presbyopia patients in China. Following this transaction, CORXEL’s pipeline will be entirely focused on cardiometabolic therapies. The proceeds from the transaction will enable CORXEL to accelerate the global clinical development of its innovative cardiometabolic pipeline.”Presbyopia is a physiological phenomenon associated with aging that results in a progressively worsening ability to see nearby objects clearly. It is caused by the gradual hardening of the lens. This results in a decline of the eye’s adjustment function, and the inability to focus the image of nearby objects on the retina, leading to a decline in near vision. Studies have shown that the onset of presbyopia typically occurs around the age of 38, reaching a prevalence rate of nearly 100 percent at the age of 52 in China. Currently, the treatment options for presbyopia are very limited. Wearing glasses requires frequent removal and insertion, causing many inconveniences in work and life. Surgery, as an irreversible and invasive operation, has very limited acceptance. There are no approved drugs for the treatment of presbyopia in China and the medical need for non-invasive, safe, efficient and reversible treatments for presbyopia remains unsolved.The NDA acceptance of LNZ100 by the National Medical Products Administration (NMPA) of the People’s Republic of China is based on the data from China Phase 3 Trial. The study was a Phase 3, multicenter, randomized, double-blind, vehicle-controlled study, including a 4-week efficacy study followed by a 6-month extension safety study, designed to evaluate the efficacy and safety of LNZ100 (an aceclidine-based ophthalmic solution) in participants with presbyopia. The objectives were to assess the potential of LNZ100 to improve near vision among Chinese presbyopia patients and to evaluate the efficacy and safety profiles. The trial has enrolled 300 participants.The results showed that LNZ100 achieved the primary endpoint and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). Results also showed (all p<0.0001) a rapid onset of action, with 84% and 69% of participants achieving two-line and three-line or greater improvements, respectively, within 30 minutes of administration. The effect was also durable, with 61% and 30% of participants continuing to achieve two-line and three-line or greater improvements, respectively, at 10 hours. In addition, LNZ100 was well tolerated, and no serious treatment-related adverse events were observed in the trial.In recent years, Everest has built a proven platform for the commercialization of innovative medicines, integrating scientific and commercial insights with coordinated access, medical, marketing, and sales (A2MS). As multiple innovative products have entered the commercialization stage, the platform’s scale and synergy effects continue to strengthen. Against this backdrop, the acquisition of late-stage assets with clear clinical value and commercial potential has become an important approach for Everest to enrich its product portfolio and expand future growth opportunities. The acquisition of Greater China rights to LNZ100 further strengthens Everest Medicines’ presence in the ophthalmology and is expected to generate synergies with its existing commercialization infrastructure, supporting the continued realization of the asset’s commercial value. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

brooke
Focus Graphite Completes Air Quality Assessment for the Lac Knife Project; Advancing Towards ESIA Completion
Focus Graphite Completes Air Quality Assessment for the Lac Knife Project; Advancing Towards ESIA Completion

OTTAWA, ON, June 8, 2026 - (ACN Newswire via SeaPRwire.com) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the. Air Quality Assessment ("AQA" or the "Study") for its 100%-owned Lac Knife Graphite Project (the "Project") located in northeastern Quebec.The Study was completed by WSP Canada Inc. ("WSP"), one of the world's leading engineering and environmental consulting firms, under the supervision and management of IOS Geosciences Inc. ("IOS"), as part of the environmental studies supporting the advancement of Lac Knife toward future permitting and development.The AQA evaluated emissions associated with the proposed open pit mine, processing facility, tailings storage facility, stockpiles, haul roads, crushing operations, and supporting infrastructure under conservative maximum operating scenarios. Atmospheric dispersion modelling using Aeromod software, was completed in accordance with the requirements of Quebec's Reglement sur l'assainissement de l'atmosphere ("RAA") and applicable guidance from the Ministere de l'Environnement, de la Lutte contre les changements climatiques, de la Faune et des Parcs ("MELCCFP").According to WSP's conclusions, the modelling results demonstrate that predicted contaminant concentrations remain in compliance with applicable Quebec ambient air quality standards and criteria under the assessed operating conditions. WSP further concluded that all evaluated contaminants met applicable regulatory thresholds. The Study also noted that prevailing winds are predominantly directed toward the south-southeast, away from nearby public infrastructure, residences, and seasonal fishing cabins."Environmental permitting is one of the most important value-creation stages in the development of any critical mineral project," said Dean Hanisch, CEO of Focus Graphite. "The completion of the Air Quality Assessment represents another key component of the broader environmental review process and brings us closer to completing the environmental studies required to support future permitting activities. As these workstreams are completed, Lac Knife continues to become increasingly de-risked from both a technical and environmental perspective while strengthening its position as a strategic North American graphite asset."The Study evaluated a broad range of potential emissions, including particulate matter, nitrogen oxides, sulphur dioxide, carbon monoxide, crystalline silica, and various metals, using a detailed atmospheric dispersion model of the Project area and surrounding receptors based on five years of regional meteorological data.Advancing Toward Environmental Assessment CompletionThe AQA forms part of the broader environmental and permitting work program being advanced at Lac Knife and represents another important milestone toward completion of the environmental and social impact assessment ("ESIA") process. With this Study now complete, the Company is advancing the remaining key environmental workstreams, including the hydrogeological assessment and dam breach analysis, which are expected to further support permitting activities and future project development.The completion of the AQA builds on a series of technical, environmental and infrastructure achievements that continue to de-risk the Project and strengthen Lac Knife's position as a strategically important North American graphite asset. As demand for secure and reliable graphite supply continues to grow, Focus remains focused on advancing the Project through the key milestones required for future development.Qualified PersonThe technical content disclosed in this news release was reviewed and approved by Rejean Girard, P.Geo. (QC), President of IOS Geosciences Inc., a consultant to the Company, and a qualified person as defined under National Instrument NI-43-101.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals — reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc., please visit http://www.focusgraphite.com.LinkedIn: https://www.linkedin.com/company/focus-graphite/X: https://x.com/focusgraphiteInvestors Contact: Dean Hanisch CEO, Focus Graphite Inc. dhanisch@focusgraphite.com +1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things: the advancement of the Lac Knife Graphite Project toward permitting readiness and future development; the completion and timing of the remaining environmental studies required to support the environmental and social impact assessment ("ESIA") process, including the hydrogeological assessment and dam breach analysis; the anticipated completion of environmental baseline, technical and permitting workstreams; the Company's ability to obtain required permits, approvals and authorizations; the anticipated benefits of completed environmental and technical studies, including the Air Quality Assessment; the timing and completion of future project milestones; the future development, construction and operation of the Lac Knife Project; the role of the Project in supporting North American and allied critical mineral supply chains; and the Company's long-term development strategy.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300471 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

brooke
康哲药业自主研发INHBE小核酸药物CMS-D008亮相ADA大会
康哲药业自主研发INHBE小核酸药物CMS-D008亮相ADA大会

深圳, 2026年6月8日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司（867.HK/8A8.SG）（“康哲药业”）欣然宣布，其自主研发的创新药INHBE小核酸药物CMS-D008注射液（“CMS-D008”）的临床前结果在第86届美国糖尿病协会（ADA）大会（2026年6月5-8日，美国新奥尔良）以壁报形式发布。ADA大会作为全球糖尿病及代谢疾病领域规模最大、最具权威影响力的年度学术风向标，此次汇聚了来自世界各地的超过12,000名顶尖临床专家、科研学者及一线医疗工作者，共同探讨与见证前沿诊疗成果与技术创新突破。关于CMS-D008CMS-D008是康哲药业自主研发的一款皮下注射的siRNA药物，靶向抑制肝脏的抑制素亚基βE（INHBE）基因表达，下调INHBE编码蛋白激活素E（Activin E）水平，从而降低脂肪代谢通路Activin E-ALK7的活化，有效减少脂质堆积，显示出减脂不减肌、长期高质量减重的潜力。目前，CMS-D008的健康受试者I期临床试验正在稳步推进中；未来拟开发治疗腹型肥胖以及相关代谢性疾病。CMS-D008展现出令人鼓舞的非临床数据。本次在ADA大会发表CMS-D008的临床前研究结果显示，在肥胖动物模型中，CMS-D008可高效持续抑制INHBE表达，在不影响肌肉的情况下，获得明显的减重减脂效果，且安全性良好，有望实现健康减重。具体信息如下：标题：CMS-D008可特异性抑制INHBE mRNA，并在临床前研究中实现了针对脂肪的减重效果摘要号：3079-LB展示形式：壁报时间：2026年6月7日01:30 PM - 02:30 PM（当地时间）地点：Hall D-E研究结果：- 在高脂饮食诱导的人源化INHBE肥胖小鼠（hINHBE DIO 小鼠）模型中，CMS-D008可显著降低肝脏中INHBE mRNA及血清中靶蛋白Activin E的水平，进而显著降低小鼠的体重、体脂、不同部位脂肪，且不影响小鼠的肌肉含量。- 在肥胖食蟹猴模型中，CMS-D008也可显著降低肝脏中INHBE mRNA及血浆中靶蛋白Activin E的表达，并显著抑制因持续摄入高脂饮食而引起的体重上升。此次研究成果入选ADA大会，体现了CMS-D008在肥胖/代谢治疗领域的科学价值与临床潜力受到国际学术界的关注。CMS-D008亦可与康哲药业临床开发阶段的自研创新药CMS-D005（GLP-1R/GCGR双重激动剂）形成协同，有望实现高效的减重获益与长期的成果维持，为患者提供更全面的治疗方案。康哲药业将自主研发作为长期发展的核心驱动力，持续深耕前沿创新领域。目前已有包括CMS-D008在内的6款拥有全球权益的自研产品进入临床阶段，另有逾20项自研项目稳步推进临床前研究。未来，康哲药业将继续聚焦未被满足的临床需求，高效推动产品的研发与商业化进程，以更全面、创新的疗法惠及广大患者。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心肾代谢/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ashley
龙丰低估值叠加高股息 价值显现

香港, 2026年6月8日 - (亚太商讯 via SeaPRwire.com) - 龙丰集团（2290）刚于周五挂牌上市，公开发售超过660倍。按周五收市价计，市值约14.05亿港元，公司预估2026财年纯利约2.65亿港元，即2026年预测市盈率只有5.3倍，大幅低于同业如DFI零售集团（22.2倍）、莎莎国际（26.8倍）及国际家居零售（12倍），反映其估值远低于同业水平，存在较大的重估空间，对投资者而言具备良好的配置价值。此外，龙丰上市后预期每年派息不少于可分配溢利的50%，按现价计算股息率约达9.4%，远超同业普遍的3%至6%及行业平均4%水平。当前同业估值偏高且回报有限，龙丰却能同时提供低估值与高股息，性价比优势不言而喻。基本面稳固加上全渠道发力，后市可为投资最重要的是看公司的前景及基本面。龙丰现有31间分店，主打“一站式”购物体验，吸引大量本地消费者及游客。公司计划未来三个财年新增18至21间门店，考虑到其新店平均仅需3个月内即达至收支平衡，2至8个月内回本，足见其营运效率与盈利能力在行业中具备无可比拟的竞争优势。此外，龙丰单店可售SKU超过9,000个，涵盖美容护肤、保健品、医药、母婴等11个核心品类，惟公司并未止步，持续拓展商品组合和种类，并深化自家品牌发展。自家品牌具备较高毛利及差异化优势，有助进一步提升品牌价值与盈利能力。除线下扩张外，龙丰同步推进线上渠道建设，实现线上线下协同发展。公司计划通过目前合作的天猫、京东等主流电商平台加强销售，同时积极布局抖音等新兴社交电商渠道，通过内容营销触达更广泛的中国内地消费群体，持续完善线上销售网络。尽管目前线上业务占比仍然较低，但随着消费模式转变，相关渠道具备较大成长空间。公司亦计划持续优化会员体系及强化数据分析能力，以提升转化率及用户黏性，同时推动线上与线下库存及销售协同，提升整体营运效率。随着全渠道策略逐步深化，龙丰有望在拓阔收入来源的同时，提升经营灵活性与资源配置效率，为未来业绩提供持续支撑。供应链垂直延伸，盈利质量持续提升龙丰已建立覆盖全球的采购体系，与超过600家供货商保持合作，来源涵盖日本、韩国及欧美市场，为产品多样性及成本竞争力提供稳固支撑。公司更计划透过策略投资及并购延伸至上游供货商及OEM制造端，全面提升供应链掌控力。随着中间环节减少及规模效应释放，成本控制能力持续改善，毛利率已由2023财年的约24.9%提升至2025财年的约31.6%。随着未来逐步参与上游环节，公司在产品定价、产品开发及供应节奏上将具备更高灵活性，亦有助支持自有品牌发展，进一步提升盈利质量。对市场而言，这类由零售端向上游供应链延伸的模式升级，往往为估值提供重新定价的契机。龙丰集低估值及高股息于一身。在业绩持续增长的同时，供应链延伸、门店扩张及全渠道发展等发展策略清晰落地，为未来提供多重支撑，而稳定派息政策则构建可靠的现金回报基础。相比同业动辄20倍以上市盈率水平，龙丰在估值与回报两方面均具明显优势。在估值尚未充分反映其盈利质素及成长潜力的情况下，随着业绩兑现、规模效应释放及业务结构优化逐步体现，市场对其盈利质素的认知有望提升。对于同时关注增长与收益的投资者而言，龙丰的价值正逐步显现。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ashley
C.banner to Acquire Controlling Stake in Benyuan Zhishu to Establish Dual-core Businesses: Footwear + AI Data

HONG KONG, Jun 8, 2026 - (ACN Newswire via SeaPRwire.com) - C.banner International Holdings Limited (Stock Code: 1028.HK, hereinafter referred to as "C.banner" or the "Group") announced that it has signed an investment agreement with Benyuan Zhishu, a leading domestic AI data service provider, and its shareholders: The Group will acquire controlling equity in Benyuan Zhishu through existing equity purchase and new share subscription, incorporating it into the Group's consolidated financial statements after the transaction is completed. With this, C.banner has formally established a dual-core business framework of "Footwear + Artificial Intelligence Data" while maintaining stable operations in its footwear business.This is a strategic layout that integrates an AI data business that has demonstrated profitability and has been validated by top-tier customers over the long term—its growth is based on real revenue and profit.I.Rationale for Data: The Competition in AI is Shifting from "Computing Power" to "Experience"The competition in artificial intelligence is undergoing a foundational shift. Over the past decade, outcomes were mainly determined by computing power and model architecture; however, as public data is gradually absorbed by large models and computing power and algorithms become increasingly common, the next critical bottleneck is no longer "whose model is bigger," but "who can continuously provide models with new, more complex, real-world high-quality experiences."This is precisely the rare and critical value of this field: computing power can be purchased, algorithms can be replicated, but scaling and verifying the transformation of expert human judgments and real-world physical interaction feedback into model-trainable data is challenging, slow, and not easily expedited by capital—making it the truly essential step in the industry. The industry has identified 2026 as the "Year of Data Scaling" for embodied intelligence, and the market is repricing accordingly: In 2025, Meta invested approximately $14.3 billion, corresponding to a valuation of around $29 billion, in data annotation company Scale AI, reflecting a shift in the perception of AI data from a "cost item" to a "strategic asset."II.Rationale for Benyuan Zhishu: Positioned at the Most Critical and Irreplaceable Step in the Value ChainBenyuan Zhishu, established in 2015, operates upstream in the artificial intelligence value chain, focusing on converting human expert knowledge and experience into high-quality, trainable and verifiable data for AI models. In contrast to low-barrier general annotation services, it specializes in data services with high technological difficulty and strict professional requirements. It has grown into one of the few domestic providers capable of delivering comprehensive data services for large models, world models, and embodied intelligence, occupying a scarce position in the "Physical AI" wave.Its competitive advantage has been forged through long-term validation by the most demanding customers and the most challenging tasks. Benyuan Zhishu serves leading domestic large model infrastructure providers, top-tier internet platforms, frontline game publishers, and leading embodied intelligence companies, undertaking high-difficulty, quality-demanding data tasks—organizing professionals in fields such as mathematics, coding, law, and medicine to perform expert-level annotations, building evaluation datasets to measure the true capabilities of models, reconstructing virtual environment data for world models, and collecting real-world physical interaction data for embodied intelligence. These collaborations require stringent entry barriers, long-term adaptation, and continuous quality validation. Benyuan Zhishu has become the exclusive data supplier for several high-value data categories for related clients, demonstrating strong customer loyalty and sustainability. With nationwide delivery centers, a crowdsourced network of hundreds of thousands of domain experts, and proprietary data platforms, Benyuan Zhishu is capable of large-scale delivery under high information security standards.It is also a profitable AI company. For the fiscal years ending December 31, 2024 and 2025, Benyuan Zhishu achieved revenues of approximately RMB 146.5 million and RMB 156.2 million, respectively, with post-tax net profits of approximately RMB 7.1 million and RMB 11.1 million. According to its latest management accounts, its revenue for the first five months of 2026 has seen strong growth. In an AI environment heavily reliant on external financing, a data company built on real orders and revenue growth, and already profitable, is distinctive.III.Rationale Behind the Structure: Stable Investment, Dual Engines, and Preserved NeutralityThe transaction structure balances the interests of the buyer, seller, and customers.Stable investment: The transaction is financed using internal Group resources. The footwear business of C.banner continues to generate stable operating cash flows and maintain a net cash position, providing a financial foundation for the growing AI data business without relying on large-scale external financing.Growth-focused Capital Allocation: The share subscription consideration in this transaction will be used to expand Benyuan Zhishu’s production capacity and technology development; simultaneously, the founding team will retain partial equity to align their interests with the Group.Preserved Operational Neutrality: Upon transaction completion, Benyuan Zhishu will retain its independent brand and operate independently, implementing data isolation mechanisms. Since C.banner itself does not engage in AI model development nor compete with Benyuan Zhishu’s customers, industry competitors of Benyuan Zhishu’s clients can continue collaborating with the same neutral supplier with confidence. For a data company, a capital structure that does not compromise neutrality is especially crucial. Moreover, Benyuan Zhishu's data and data governance capabilities can also be applied to the Group's footwear retail supply chain, design, and marketing segments, enhancing the operational efficiency of the traditional core business through artificial intelligence.IV.Management StatementThe management of C.banner stated: “We believe that high-quality data is one of the most critical and scarce infrastructures in the era of artificial intelligence. This transaction allows the Group to enter this rapidly growing sector while maintaining a stable foundation in the consumer industry. We look forward to working with Benyuan Zhishu to continuously provide 'data fuel' of high quality to China's AI industry, creating sustainable long-term value for our shareholders under the dual-core business framework.”Benyuan Zhishu’s founder and CEO, Li Niyong, will also issue a public letter on the same day to share the company’s vision and the significance of this cooperation. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

brooke
HKTDC’s ‘Hong Kong Tech Pavilion’ at Paris VivaTech 2026 to showcase 24 Hong Kong startups to connect global investment opportunities
HKTDC’s ‘Hong Kong Tech Pavilion’ at Paris VivaTech 2026 to showcase 24 Hong Kong startups to connect global investment opportunities

HONG KONG, Jun 7, 2026 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) will host a "Hong Kong Tech Pavilion" at Viva Technology (VivaTech) 2026, Europe’s premier annual startup and technology summit in Paris, from next Wednesday, 17 to Saturday, 20 June. In collaboration with our strategic partner, the Hong Kong Economic and Trade Office in Brussels, the Pavilion will bring together 24 Hong Kong startups to showcase innovations in artificial intelligence and robotics, health technology, and sustainability and climate technology. A series of thematic seminars, startup pitching sessions, and networking receptions will also be held to facilitate exchanges between global investors, buyers, and Hong Kong startups, fostering international collaboration. Several key partners, including Hong Kong Science and Technology Parks Corporation, Hong Kong Polytechnic University, Hong Kong Productivity Council, Hong Kong University of Science and Technology, and Cyberport, support the initiative.HKTDC’s Chris Lo, Regional Director, Europe, Central Asia & Israel, stated: "Hong Kong is actively developing into an international innovation and technology hub. As one of the key enablers, the HKTDC supports enterprises in going global by curating overseas platforms and facilitating cross-regional exchanges. Building on last year's success, we are further expanding the Hong Kong Tech Pavilion at VivaTech this year to deepen connections among startups, tech leaders, large corporations, and investors, fostering innovative collaborations and business matchmaking, assisting innovation and technology enterprises in exploring overseas markets, and showcasing to Europe Hong Kong's unique advantages as an international innovation hub."During the exhibition, the HKTDC will organise a series of events, including thematic seminars, startup pitching sessions, and networking activities, to explore future development trends for Hong Kong startups and global collaboration opportunities.Shirley Yung, Special Representative for Hong Kong Economic & Trade Affairs to the European Union, will attend and deliver a keynote speech at the thematic seminar and networking reception titled "Building Resilient Tech Ecosystems: Powering the Next Wave of International Tech Leadership from Hong Kong" on 19 June. The seminar will feature three main segments: "Launching from Hong Kong: The Innovation Infrastructure Powering Start-up Breakthrough”, where Hong Kong Science and Technology Parks Corporation, and startups will share local success stories; "Engineering for Success: How Hong Kong’s Innovation Landscape Helps Tech Companies Achieve Market Fit'”, featuring Hong Kong Productivity Council and enterprise representatives exploring market matchmaking; and a concluding panel discussion inviting representatives from academia, incubators and technology institutions to examine how talent and infrastructure drive Hong Kong's technological development and international collaboration.Helping Hong Kong startups pitch to global investorsParticipating startups at VivaTech’s Hong Kong Tech Pavilion will showcase their innovative solutions and products to investors from around the world. Three thematic pitching sessions will be held over the first three days:17 June (afternoon): Robotics and Microelectronics theme, featuring seven enterprises showcasing their innovative achievements including Bacbudy Limited, which develops intelligent wearable and robotic assistive devices for the lower back, and Cybercrystal Technology Co., which researches next-generation robotic optical tactile skin.18 June (morning): Artificial Intelligence and Health Technology theme, featuring eight enterprises presenting breakthrough innovations in AI and health technology including Eieling Technology, which develops portable chronic liver disease medical diagnostics and AI applications, and Point Fit Technology, which develops wearable health monitoring and intelligent sports solutions.19 June (noon): Sustainability and Climate Technology theme, featuring seven enterprises including Albacastor Technology, which develops eco-friendly industrial oil-removal and deodorising ventilation systems, and Green Vigor, which develops energy recovery and green power generation technologies.Additional events include: On the first day (17 June), the thematic seminar "Europe to Hong Kong: Building a Startup Between Two Ecosystems" will be moderated by Christopher Lai, Director, France, Spain & Portugal of HKTDC, inviting French entrepreneurs to share their experiences in business expansion across Europe and Hong Kong, analysing the differences between the two ecosystems, and exploring how to leverage Hong Kong as a platform for entering the Asian market and securing funding.On the exhibition’s second day (18 June), Hong Kong Science and Technology Parks Corporation will host the "HKSTP Global Mixer: Inside Hong Kong’s Startup Acceleration Playbook", exploring how Hong Kong connects with the global innovation and technology ecosystem and its advantages in talent and investment. In the same afternoon, Hong Kong Polytechnic University will host the “Breaking Barriers with Autonomous Systems: Transforming Industries with AI Innovation”, showcasing Hong Kong’s unique position in harnessing the power of AI and its world-class academia to develop a globally leading innovation hub. That evening, the "Hong Kong Tech Night: Where Innovation Meets Opportunity" networking event will bring together the innovation and technology communities of Hong Kong and France, fostering collaboration between both sides in talent, funding, and market expansion.The VivaTech 2026 Hong Kong Tech Pavilion is located at Booth 1C11, Hall 7.1, Paris Expo Porte de Versailles. The 10th edition of VivaTech is expected to attract more than 180,000 visitors, 14,000 global startups, and 3,600 investors, bringing together industry leaders from around the world to become a key focal point of the international innovation and technology ecosystem.VivaTech Hong Kong Tech Pavilion is an Economic and Trade Express flagship event, which helps Hong Kong SMEs and startups explore overseas market opportunities while attracting more companies to invest and establish operations in Hong Kong.List of 24 Start-ups at the Hong Kong Tech Pavilion: CategoryCompany Name1.     Sustainable & Climate TechnologyAlbacastor Technology Limited2.     AIGreen Limited 3.     Asgard Group Limited 4.     Formwork IO5.     Green Vigor Limited6.     Laputa Eco-Construction Material Company Limited7.     LeafIoT Technology Limited8.     Plasticvore Chain Ltd 9.     AI and Software Solutions Cogniser Infotech Ltd10.  D-Engraver Limited11.  Midas Analytics Limited 12.  OxGen Holdings Limited13.  Pantheon Lab Limited14.  SagaDigits Limited15.  Robotics and Microelectronics TechnologyAnlaseo Technology Limited16.  Bacbudy Limited17.  Cybercrystal Technology Co., Limited18.  Harmony SkyTech Limited19.  Oriental Materials Hong Kong Limited20.  Robocore Technology Limited21.  Health TechnologyEieling Technology Limited22.  Hong Kong Bionic Beet Robotics Limited23.  Point Fit Technology Limited 24.  UniversityThe Hong Kong Polytechnic UniversityPhoto download: https://bit.ly/3RxuMDZThe HKTDC will host the Hong Kong Tech Pavilion at VivaTech 2026. The picture shows last year’s pavilion.  During VivaTech, the HKTDC will host a series of exciting events including thematic seminars, startup pitching sessions, and networking receptions, and will arrange business matchmaking with representatives from various enterprises and organisations to assist startups in exploring the European market.Websites: https://vivatech.com/exhibitors/hktdc-hong-kong-trade-development-councilMedia enquiriesFor enquiries, please contact HKTDC’s Communications & Public Affairs Department:Winnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

brooke
iHerb Expands Consumer Benefits Across Asia with 618 Shopping Festival
iHerb Expands Consumer Benefits Across Asia with 618 Shopping Festival

IRVINE, CA, June 7, 2026 - (ACN Newswire via SeaPRwire.com) - iHerb, a global e‑commerce platform specializing in health and wellness products, has officially launched its 2026 “618 Peak Shopping Festival.” As a brand with a 29‑year heritage, this initiative brings a range of promotional offers and localized services to customers in Hong Kong and Southeast Asia, reflecting the company’s ongoing commitment to enhancing accessibility and customer experience across international markets.Founded in 1996, iHerb has expanded its operations to 185 countries and regions and now serves more than 11 million active users worldwide. Through its direct sourcing model and global fulfillment network, the company has focused on providing consumers with access to a broad range of international health, wellness, beauty, and personal care products.Unlike traditional cross-border retail models that often involve multiple intermediaries, iHerb purchases products directly from manufacturers and distributes them through its own warehouse network. The company stated that this approach helps improve supply chain transparency and product traceability while streamlining international delivery.As part of the 618 campaign, iHerb highlighted a selection of products from popular categories frequently purchased by consumers, including dietary supplements, personal care products, sports nutrition items, and beauty products.Among the featured products are:California Gold Nutrition LactoBif(R) 30 Billion Probiotics (CGN00965), a probiotic supplement packaged in individually sealed blister packs for convenient storage and transportation.Doctor's Best High Absorption Magnesium (DRB00087), a magnesium supplement formulated using Albion(R) TRAACS(R) chelation technology.Nature's Way Alive! Hair, Skin and Nails Gummies (NWY11534), a strawberry-flavored gummy supplement containing vitamins, collagen, and other nutritional ingredients.Metagenics OmegaGenics(R) Fish Oil EPA-DHA (MTG93873), a fish oil supplement containing EPA, DHA, and omega-3 fatty acids.ProHealth Longevity NMN Pro 1000 (PHV77904), an NMN supplement designed for adult consumers interested in wellness-focused nutritional products.The company noted that these products represent some of the diverse categories available on the platform, which currently offers nearly 3,000 brands and more than 50,000 products globally.To commemorate its 29th anniversary and the 618 Shopping Festival, iHerb announced several promotional initiatives for customers in Hong Kong and Southeast Asia:New customers can use the code WELCOME7 to receive a first-order discount.From June 11 to June 20, customers can use 618SALE26 for sitewide promotional savings.Additional regional promotions are available through the end of June using code 6HK75, subject to applicable terms and conditions.Customers in Hong Kong may qualify for free shipping on eligible orders and access local express delivery options.In addition to promotional activities, iHerb continues to expand localized services across Asian markets. Customers can shop through the company's website and mobile application, with support for local currencies and multiple payment methods, including credit cards and digital wallets.As iHerb marks its 29th anniversary, the company stated that it will continue investing in supply chain infrastructure, customer service, and regional fulfillment capabilities to support consumers seeking access to international health and wellness products.Company: iHerb, LLCContact Person: Kelly ChaiEmail: china.sm@iherb.com Website: iherb.com Telephone: (1) 951 6163600 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

brooke
Central Asia visit drives multi-sector collaboration, Business delegation signed 66 MoUs and agreements to seize Belt and Road opportunities
Central Asia visit drives multi-sector collaboration, Business delegation signed 66 MoUs and agreements to seize Belt and Road opportunities

Tashkent, Uzbekistan, Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - A business delegation led by the Chief Executive of the Hong Kong Special Administrative Region (HKSAR), John Lee, and organised by the Hong Kong Trade Development Council (HKTDC), completed its first stop in Kazakhstan from 1 to 3 June and are now visiting Tashkent, the capital of Uzbekistan, for the final leg of its Central Asia tour from 4 to 5 June. During the visit, the delegation met with senior representatives of the local government and business communities, successfully advancing collaboration opportunities across multiple sectors.The HKTDC will follow up on key projects facilitated during the visit by providing professional post-‘mission business matching and support services, with a view to expediting project implementation while continuing to assist Hong Kong enterprises in exploring further international cooperation opportunities.The business delegation facilitated the signing of 66 memoranda of understanding (MoUs) and agreements during its visit to Kazakhstan and Uzbekistan, covering areas such as trade, investment, finance, technology and aviation. In addition, 15 cooperation agreements were signed at the government level, while non-delegation members signed 15 MoUs in areas including academia and culture, bringing the total number of agreements and MoUs signed to 96. These outcomes have laid a solid foundation for deepening economic and trade ties among Hong Kong, the Chinese Mainland, Kazakhstan and Uzbekistan, underscoring Hong Kong’s role as a key platform for Mainland enterprises to go global and further promoting long-term collaboration with Central Asian markets. Looking ahead, the parties look forward to welcoming more Central Asian enterprises to Hong Kong and HKTDC’s flagship international conferences and exhibitions, including the Belt and Road Summit and InnoEX, to capitalise on Hong Kong’s strengths as an international business and trading hub and further deepen cooperation.During its stay in Uzbekistan, the delegation met with senior officials, trade bodies and business representatives, including the Ministry of Investment, Industry and Trade (MIIT) of Uzbekistan and Uzbekistan Chamber of Commerce, and IT Park Uzbekistan, to gain in-depth insights into the country’s economic developments, market environment and investment opportunities.Summing up the Central Asia visit, Mr Lee said: “The purpose of this visit is threefold. First, to further explore emerging markets and lay a solid foundation for long-term economic and trade development. Second, to strengthen government-to-government relations and promote closer bilateral cooperation. Third, to establish a hub-to-hub cooperation model.During the visit, I led a delegation of 75 business leaders from Hong Kong and Mainland enterprises to Kazakhstan and Uzbekistan — the two largest economies among the five Central Asian countries. The delegation attended more than 20 events and inspected multiple projects in the finance, innovation and technology, and infrastructure sectors. The visit was highly successful and achieved eight major outcomes.”Mr Lee held meetings with the Presidents, Prime Ministers and other senior officials of the two countries. Both sides agreed to strengthen high-level communication and pursue multi-faceted collaboration. The Government of Uzbekistan has agreed to establish a Consulate General in Hong Kong. In addition, multiple agreements were signed, including projects with substantial investment value.Both sides recognised that the hub-to-hub cooperation model will create broader and deeper collaboration between the two regions and drive high-quality development. They will increase high-level mutual visits, support each other’s promotional activities and jointly expand their networks.”To deepen economic and trade cooperation, the HKSAR Government and the HKTDC jointly hosted a business dinner in Uzbekistan, attracting around 230 business leaders and senior officials. Prof Frederick Ma, Chairman of the HKTDC, said at the dinner: “The Central Asia visit has delivered fruitful outcomes and once again reaffirmed the trust placed by Central Asian countries in Hong Kong’s role as a bridge. In tapping emerging markets, such as Kazakhstan and Uzbekistan, Hong Kong, with its international credibility, robust institutional framework, world-class professional services and the HKTDC’s global network, serves not only as a key springboard for Mainland enterprises to go global, but also as a gateway for overseas enterprises to enter the Mainland market, effectively facilitating two-way investment and trade flows. This virtuous cycle of going global and attracting foreign investment fully demonstrates Hong Kong’s irreplaceable value under the Belt and Road Initiative as well as the HKTDC’s strengths as the preferred platform for enterprises pursuing two-way expansion.”The delegation comprised business leaders from Hong Kong and 17 provinces and municipalities across the Chinese Mainland, spanning a broad range of sectors, including financial and professional services, logistics and transportation, innovation and technology, trade, green industries as well as the media. For the first time, representatives from journalism associations joined the delegation, in response to the Policy Address’s initiative to assist the local media in expanding their network beyond Hong Kong and telling the good stories of Hong Kong.  During its Kazakhstan visit, the delegation facilitated 43 MoUs and agreements, including:1.Hong Kong Trade Development Council (HKTDC) and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"2.Hong Kong Trade Development Council (HKTDC) and Astana International Financial Centre (AIFC)3.Hong Kong Trade Development Council (HKTDC) and Satbayev University4.Airport Authority Hong Kong and Almaty International Airport5.Belt and Road General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"6.Belt and Road General Chamber of Commerce and Commex HK Link Digital Trading Company Limited and Eurasian Trading System Export” International Commodity Exchange (ETSE)7.Belt and Road General Chamber of Commerce and JINGSH CONSULTING LLP8.Chinese Manufacturers Association and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"9.Cyberport and Astana Hub10.Federation of Hong Kong Industries (FHKI) and Ministry of Artificial Intelligence and Digital Development in Kazakhstan11.Hong Kong Exchange and Clearing Limited and Astana International Exchange (AIX)12.Hong Kong Exchange and Clearing Limited and Astana International Financial Centre (AIFC)13.Hong Kong Science and Technology Parks and Astana Hub14.Hong Kong-Shenzhen Innovation and Technology Park Ltd. and Astana Hub15.The Hong Kong General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"16.Law Society of Hong Kong and National Bar Association of Kazakhstan17.BOCHK and Bank of China Kazakhstan and Baiterek18.BOCHK and Samruk Kazyna19.Bosera International Asset Management Limited and JSC "Halyk Bank of Kazakhstan"20.Cathay Pacific and Almaty International Airport and Almaty City Government (Tourism Development)21.China International Capital Corporation Limited and Freedom Holdings22.China International Capital Corporation Limited and Samruk Kazyna23.China International Capital Corporation Limited and Astana International Financial Centre (AIFC)24.China International Capital Corporation Limited and Air Astana25.Deloitte China and Universal Energy Co., Ltd.26.Ewpartners Investment Management Limited and Dasco Capital Ltd.27.Ewpartners Investment Management Limited and Astana International Financial Centre (AIFC)28.Ewpartners Investment Management Limited and Jiangsu Solicitude Medical Technology (Group) Limited and Samruk-Kazyna Invest LLP29.Goldford Group and Gas Energy Solution LLP30.Hong Kong News Executives’ Association and The Newspaper Society of Hong Kong and Khabar Agency JSC31.Jardine Matheson and KIDF32.Jiaxin International Resources Investment Limited and Industry and Construction of the Republic of Kazakhstan33.Koln 3D Technology (Medical) Limited and Kazakh Research Institute of Oncology and Radiology34.PCCW Limited and Kazakhtelecom35.PCCW Limited and Khabar Agency JSC36.SCMP and Astana International Financial Centre (AIFC)37.SCMP and GOBI PARTNERS and Astana Hub and Khan Tengri Innovation Hub38.Soy-Sky FarmTech Company Limited (Hong Kong) and JSC NC Food Contract Corporation of Kazakhstan39.Standard Chartered Bank and Development Bank of Kazakhstan40.Standard Chartered Bank and Hangzhou CIEC Group Co., Ltd.41.Templewater Limited and Freedom Holdings42.The Standard and Freedom Horizons43.Walvax Biotechnology Co., Ltd. and Gold Astrum LLC  During its Uzbekistan visit, the delegation facilitated 23 MoUs and agreements, including:1.Hong Kong Trade Development Council (HKTDC) and Chamber of Commerce and Industry of Uzbekistan (CCIU)2.Hong Kong Trade Development Council (HKTDC) and IT Park Uzbekistan3.Airport Authority Hong Kong and Fly Khiva Group4.Belt and Road General Chamber of Commerce and Commex HK Link Digital Trading Company Limited and SINOCHEM PLASTICS GROUP “MCHJ XK”5.Belt and Road General Chamber of Commerce and Chamber of Commerce and Industry of Uzbekistan (CCIU)6.Belt and Road General Chamber of Commerce and JINGSH CONSULTING LLP7.Chinese Manufacturers' Association of Hong Kong and Chamber of Commerce and Industry of Uzbekistan (CCIU)8.Federation of Hong Kong Industries (FHKI) and Tashkent City Municipality9.Cyberport and IT Park Uzbekistan10.The Hong Kong General Chamber of Commerce and Chamber of Commerce and Industry of Uzbekistan (CCIU)11.Law Society of Hong Kong and Chamber of Advocates of the Republic of Uzbekistan12.A-Grade Energy Ltd and Zarafshan Golden Group of Uzbekistan13.China International Capital Corporation Limited and National Bank of Uzbekistan14.China International Capital Corporation Limited and Tashkent City Municipality of the Republic of Uzbekistan15.Deloitte China and Orient Group and CITIC16.Goldford Group and Automated Solutions Center17.Templewater Limited and Uzbek-Oman Investment Company LLC18.Templewater Limited and CSCEC INTERNATIONAL MCHJXK (China State Construction International Holdings Limited)19.Templewater Limited and Tashkent City Municipality of the Republic of Uzbekistan20.The Standard and Tashkent City Municipality of the Republic of Uzbekistan21.Changchun GeneScience Pharmaceutical Co., Ltd. with Vita Group Farm22.Guangzhou Pharmaceutical Holdings Limited and ADN Pharm-Sanoat Uzbekistan23.Shaanxi Tirain Science & Technology Co., Ltd. and Geodesy, Cartography and Remote Sensing Department, Cadastral Agency under the State Tax Committee of the Republic of UzbekistanOther non-delegate organisations have also taken this opportunity to establish collaborations in various fields, including education, culture, and more:1.A-Grade Energy Ltd and Ministry of Artificial Intelligence and Digital Development of the Republic of Kazakhstan2.A-Grade Energy Ltd and Freedom Holdings3.China Mobile International Limited and Qazpost-YTO4.City University of Hong Kong and JSC "Center for International Programs under the Ministry of Science and Higher Education of the Republic of Kazakhstan5.City University of Hong Kong and Satbayev University6.City University of Hong Kong and Tashkent State Technical University7.Education University of Hong Kong and Nazarbayev University8.HKT and Education University of Hong Kong9.Hong Kong Polytechnic University and Nazarbayev University10.Hong Kong Polytechnic University and El-Yurt Umidi Foundation11.Hong Kong Polytechnic University and New Uzbekistan University (NUU)12.Thei and BILIM-INNOVATION International Social Foundation13.Thei and L.N. Gumilyov Eurasian National University14.CCBI and Uzbekistan BA Association15.West Kowloon Cultural District Authority – Hong Kong Palace Museum and State Museum of History of UzbekistanPhoto download: https://bit.ly/4fmUpRLSumming up the Central Asia visit, John Lee, Chief Executive of the HKSAR, said: “The purpose of this visit is threefold. First, to further explore emerging markets and lay a solid foundation for long-term economic and trade development. Second, to strengthen government-to-government relations and promote closer bilateral cooperation. Third, to establish a hub-to-hub cooperation model.During the visit, I led a delegation of 75 business leaders from Hong Kong and Mainland enterprises to Kazakhstan and Uzbekistan — the two largest economies among the five Central Asian countries. The delegation attended more than 20 events and inspected multiple projects in the finance, innovation and technology, and infrastructure sectors. The visit was highly successful and achieved eight major outcomes.”Prof Frederick Ma, Chairman of the HKTDC, joined John Lee, Chief Executive of the HKSAR, senior officials of the HKSAR Government and members of the delegation in meeting the media, noting that the Central Asia visit led by the Chief Executive has successfully opened doors to business cooperation with Central AsiaThe HKSAR Government and the Hong Kong Trade Development Council (HKTDC) jointly hosted a business dinner in Uzbekistan, attracting around 230 business leaders and senior officialsProf Frederick Ma, Chairman of the HKTDC, said at the dinner: “The Central Asia visit has delivered fruitful outcomes and once again reaffirmed the trust placed by Central Asian countries in Hong Kong’s role as a bridge. In tapping emerging markets, such as Kazakhstan and Uzbekistan, Hong Kong, with its international credibility, robust institutional framework, world-class professional services and the HKTDC’s global network, serves not only as a key springboard for Mainland enterprises to go global, but also as a gateway for overseas enterprises to enter the Mainland market, effectively facilitating two-way investment and trade flows. This virtuous cycle of going global and attracting foreign investment fully demonstrates Hong Kong’s irreplaceable value under the Belt and Road Initiative as well as the HKTDC’s strengths as the preferred platform for enterprises pursuing two-way expansion.”During its visit to Uzbekistan, the delegation facilitated 23 memoranda of understanding (MoUs) and agreementsThe delegation met with representatives of the Ministry of Investment, Industry and Trade (MIIT) of Uzbekistan to gain in-depth insights into bilateral trade and investment opportunities. During the meeting, Prof Frederick Ma, Chairman of the HKTDC, met with Khodjayev Jamshid Abdukhakimovich, Deputy Prime Minister of the Republic of UzbekistanThe delegation met with representatives of the Uzbekistan Chamber of Commerce to gain in-depth insights into the country’s economic developments, market environment and investment opportunitiesThe delegation visited IT Park Uzbekistan to learn about the latest developments in innovation and technologyMedia enquiriesHKTDC’s Communications & Public Affairs Department:Johnny Tsui Tel: (852) 2584 4395  Email: johnny.cy.tsui@hktdc.orgSerena Cheung  Tel: (852) 2584 4272  Email: serena.hm.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

brooke
云英谷科技登陆港交所主板 内地OLED显示驱动芯片领军企业登陆国际资本市场

香港, 2026年6月5日 - (亚太商讯 via SeaPRwire.com) - 全球显示驱动芯片市场正经历深刻变革。AMOLED 凭借轻薄、低功耗、高对比度及可弯曲等特性，正加速取代传统 LCD，成为智能手机、可穿戴设备及 VR/AR 头戴装置的主流显示方案。随着 AMOLED 渗透率持续攀升，上游显示驱动芯片的战略地位愈发关键。2026 年 5 月 27 日，云英谷科技股份有限公司（「云英谷科技」或「公司」，股份代号：3310）正式登陆香港联交所主板，作为内地 OLED 显示驱动芯片领军企业登陆国际资本市场。本次上市全球发售获市场高度认可，香港公开发售录得 3559.68 倍超额认购，国际配售获 7.05 倍超额认购，最终发行价定为每股 20.81 港元；上市首日股价表现强劲，收报 39.9 港元，较发行价上涨 91.7%，全日成交 1681.27 万股，总成交金额 5.35 亿港元，资本市场反应热烈。AMOLED 芯片国产替代的领跑力量云英谷科技于 2012 年成立，是一家专注于 AMOLED 显示驱动芯片及 Micro-OLED 显示背板驱动的 Fabless 设计公司。根据弗若斯特沙利文报告，按 2024 年销量计，公司为全球智能手机 AMOLED 显示驱动芯片第五大供应商、中国大陆最大供应商；在中国大陆市场销量排名第三，市场份额达 12.4%，居本土供应商首位。在 Micro-OLED 显示背板驱动领域，公司全球排名第二，市场份额高达 40.7%，仅次于日本索尼，在两大高增长显示技术赛道均稳居头部梯队。AMOLED 显示驱动芯片前装品牌市场认证门槛极高，云英谷科技是中国大陆首家通过品牌客户认证、唯一累计出货超千万颗的企业。截至 2024 年底，产品已应用于全球多个头部智能手机品牌的超 10 个产品系列，多为独家或核心供应商，客户黏性与先发优势突出。在 VR/AR 核心元件 Micro-OLED 显示背板驱动领域，公司为全球先行者，2024 年全球市占率超四成。随着 AI 可穿戴需求爆发，该业务收入从 2024 年约 7504 万元人民币大增近三倍至 2025 年的 2.96 亿元，形成手机 + 次世代显示双引擎增长格局。硬核研发与品牌信赖筑牢护城河全球显示驱动芯片长期由韩国、中国台湾地区厂商主导，云英谷科技凭借全栈自研技术打破格局。公司掌握显示驱动芯片设计、驱动补偿算法、像素补偿电路布局三大核心技术，围绕两大主轴开发近 20 个产品系列，核心性能达行业前列。其自研算法与电路大幅提升显示效果与模组良率，成为大陆少数具备完整算法能力的驱动芯片厂商。产品层面，公司率先推出 LTPO 驱动芯片（支持 1–120Hz 动态刷新率），亦是大陆首家实现 RAM-less AMOLED 驱动芯片品牌量产的企业，有效推动 AMOLED 向中低端手机渗透。在 Micro-OLED 领域，公司为全球首家推出超高分辨率、高发光频率驱动方案的厂商，成为高阶 VR 设备主流选择。2023 至 2025 年，公司累计研发投入达 6.85 亿元，占总收入 25.2%，研发费用复合增长 22.6%。高强度研发支撑产品结构升级，收入由 2023 年 7.20 亿元增至 2025 年 11.06 亿元。登陆国际资本舞台 开启全新成长周期本次港股上市，云英谷科技募资将用于技术研发、产品矩阵拓展与产业链整合。公司正从手机 AMOLED 驱动芯片领先者，向全品类显示驱动方案提供商升级：产品纵深上，加速布局 AMOLED TDDI（触控显示集成）芯片，目标 2027 年出货占比超五成；同时布局 Micro-LED 显示背板驱动，覆盖车载、商业显示、AR/VR 等场景。应用广度上，从手机、VR/AR 延伸至平板、车载、智能穿戴等中大尺寸领域，目前已与头部品牌展开验证，预计 2028 年前陆续贡献收入。随着 AI 终端、折叠屏、智能眼镜等新场景带动高性能显示需求爆发，凭借技术、客户与资本优势，云英谷科技不仅将持续引领国产替代，更有望成为定义下一代显示标准的核心力量。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ashley
Alltronics Officially Opens Malaysia Facility
Alltronics Officially Opens Malaysia Facility

HONG KONG, Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - Alltronics Holdings Limited (“Alltronics” or the “Group”) (SEHK: 833), a leading manufacturer of electronic products, announced the official opening of its manufacturing facility in Penang, Malaysia. The new operation marks an important milestone in the Group’s strategy to diversify its manufacturing footprint beyond the Chinese Mainland while deepening its production presence in Southeast Asia.The Penang facility spans approximately 60,000 square feet and houses 12 production lines, providing a monthly production capacity of 250,000 to 300,000 units. It operates as an OEM manufacturing base for industrial electronics, environmental control and electronics power modules, serving international customers. The additional capacity broadens the Group’s manufacturing scale, reflects growing customer demand and creates a platform for further business development.The opening builds on the Group’s strategic initiatives completed in 2025, including the acquisition of manufacturing operations in Penang, Malaysia, and Ho Chi Minh City, Vietnam. The move into Malaysia represented the Group’s first production foothold outside the Chinese Mainland. Following the acquisition in August 2025, the Group has expanded and upgraded the Penang facility with advanced equipment and process improvements to strengthen efficiency and quality control. It now manufactures irrigation sensors, thermostats, security devices and lithium battery packs.Mr. Lam Yin Kee, Chairman and Executive Director of Alltronics, said, “The Penang facility plays an important role in advancing the Group’s strategy to build a more diversified manufacturing network. Together with our expansion into Vietnam, we are reinforcing our production capabilities and increasing supply chain flexibility across our operations. These initiatives strengthen the Group’s resilience and agility in supporting our customers in an increasingly dynamic global environment.”Mr. Lam Chee Tai, Eric, Chief Executive and Executive Director of Alltronics, added, “The Penang operation is ramping up steadily and is already supporting a growing pipeline of orders from existing and new customers. With expanded production lines and upgraded systems, we are ready to scale output as demand increases. The Group is evaluating the potential establishment of another facility in Malaysia with comparable capacity to support the Group’s next phase of growth.” Official representatives of Malaysia, together with Alltronics’ Board of Directors and management, officiate at the ribbon-cutting ceremony for the Group’s new Malaysia facility. With 12 production lines and a monthly capacity of 250,000 to 300,000 units, Alltronics’ Malaysia facility broadens the Group’s manufacturing scale and supports growing customer demand.About Alltronics Holdings Limited (Stock code: 833)Alltronics Holdings Limited is mainly engaged in the design and manufacture of a wide range of electronic products with quality and style. The Company is a constituent stock of the Morgan Stanley Capital International (“MSCI”) Hong Kong Micro Cap Index. For more information, please visit the company website http://www.alltronics.com.hk/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

brooke
华讯马来西亚生产基地正式启用 优化多元产能布局 迈向新阶段业务增长
华讯马来西亚生产基地正式启用 优化多元产能布局 迈向新阶段业务增长

香港, 2026年6月5日 - (亚太商讯 via SeaPRwire.com) - 领先电子产品生产商华讯股份有限公司（「华讯」或「集团」）（股份代号：833）宣布其位于马来西亚槟城的生产基地正式启用。该新设施为集团多元制造布局策略的重要里程碑，标志着拓展中国内地以外产能，并进一步强化东南亚的生产网络。该槟城厂占地约60,000平方呎，设有12条生产线，每月产能达250,000至300,000件。该厂作为原始设备制造（OEM）生产基地，主要生产销往国际市场的工业电子产品、环境控制设备及电子电源模块。新增产能不仅扩大集团的整体制造规模，亦满足持续增长的市场需求，为未来业务拓展提供稳固基础。是次启用乃承接集团于2025年完成的多项策略性部署，包括收购位于马来西亚槟城及越南胡志明市的制造业务。进军马来西亚为集团首次在中国内地以外建立生产据点。集团于2025年8月完成收购槟城厂后，展开扩建及升级，引入先进设备及优化生产流程，以提升效率及质量管理水平。该设施现时生产灌溉传感器、恒温器、保安设备及锂电池组。华讯主席兼执行董事林贤奇先生表示：「槟城厂在推动集团建立更多元化制造网络的策略中发挥关键作用。配合越南业务的拓展，我们正持续强化生产能力，提升整体供应链的灵活性，有助进一步增强集团的韧性与应变能力，使我们能在瞬息万变的全球环境下更有效支持客户业务发展。」华讯行政总裁兼执行董事林子泰先生补充指：「槟城厂正稳步提升产能，并已承接现有及新客户的新增订单。随着生产线扩充及系统升级完成，产能将更趋充裕，以配合未来需求。集团亦正评估于马来西亚设立另一个具相若产能的生产基地，推动下一阶段的业务增长。」  马来西亚官方代表、华讯董事局成员及管理层于当地新厂房举行剪彩仪式。华讯马来西亚生产基地配备12条生产线，每月产能达250,000至300,000件，进一步扩大集团制造规模，满足持续增长的客户需求。有关华讯股份有限公司（股份代号：833）华讯股份有限公司主要从事设计及生产多款高质量且时尚的电子产品。本公司为明晟（「MSCI」）香港微型指数成份股。有关详情，请浏览网页http://www.alltronics.com.hk/。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ashley
ERA 2026: HighTide Therapeutics Presents New Findings Supporting HTD1801’s Renoprotective Potential in Oral Presentation
ERA 2026: HighTide Therapeutics Presents New Findings Supporting HTD1801’s Renoprotective Potential in Oral Presentation

GLASGOW / HONG KONG - Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - HighTide Therapeutics, Inc. (2511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new findings on the renoprotective effects of its lead candidate HTD1801 in an oral presentation at the 63rd European Renal Association (ERA) Congress in Glasgow, UK.HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) targeting the AMPK-NLRP3 axis. In the completed Phase III trials (SYMPHONY-1 and 2), HTD1801 demonstrated significant improvement in renal function in patients with Type 2 Diabetes Mellitus (T2DM) and baseline eGFR of 60–90 mL/min/1.73m².  Treatment of these patients with HTD1801 resulted in a mean increase of +3.08 mL/min/1.73m² in eGFR after 52 weeks (95% CI: 0.46–5.70), without evidence of hyperfiltration or fluid retention. These findings suggest that HTD1801 may differentiate from existing therapies, with the potential to delay or prevent disease progression.This study was conducted by HighTide Therapeutics in collaboration with the research team led by Academician Jiandong Jiang at the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, and further explored the mechanistic basis underlying these clinical observations. In glucose- and palmitic acid-induced podocyte injury models, HTD1801 significantly preserved podocyte viability and inhibited apoptosis. HTD1801 also restored expression of the key podocyte structural proteins nephrin and podocin, while reducing the levels of the inflammatory marker phosphorylated NF-κB and the apoptosis executioner caspase-3. In a diabetic nephropathy (DN) model, HTD1801 demonstrated dose-dependent improvements in renal architecture, reduced tubular injury scores, attenuated renal inflammatory and fibrotic changes, and drove a robust decrease in 24-hour urinary microalbumin.The study systematically demonstrated that HTD1801 suppresses podocyte inflammation and apoptosis while stabilizing glomerular structure, providing the latest findings supporting its renoprotective potential. These findings provide important scientific rationale for the development of HTD1801 as a potential disease-modifying therapy for chronic kidney disease (CKD) and other renal diseases.Abstract Title: HTD1801 Attenuates Podocyte Apoptosis and Glomerular Injury: Mechanistic Insights into RenoprotectionPresentation Number: 2243Presentation Date/Time: Thursday, June 4, 2026, 8:15 a.m. BSTFormat: Oral PresentationSpeaker: Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics"This study provides the first evidence into the renoprotective effects of HTD1801 at the podocyte and glomerular levels. The convergence of clinical and preclinical data further supports the disease-modifying potential of HTD1801 and its ability to target fundamental pathophysiologic processes in CKD or other renal diseases," said Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics. "We will continue advancing the clinical development of HTD1801 across CKD and related indications to provide more treatment options for patients worldwide."About HTD1801HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management. For more information, please visit www.hightidetx.com Contact: pr@hightidetx.com  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

brooke
ERA 2026：君圣泰医药口头报告HTD1801肾脏保护最新研究结果
ERA 2026：君圣泰医药口头报告HTD1801肾脏保护最新研究结果

香港, 2026年6月5日 - (亚太商讯 via SeaPRwire.com) - 君圣泰医药（股票代码：2511.HK），一家专注于心肾代谢系统疾病（CKM）、开发多功能多靶点疗法的创新生物医药公司，今日在英国格拉斯哥举行的第63届欧洲肾脏协会（ERA）年会上，以口头报告的形式公布了其核心产品HTD1801的肾脏保护最新研究结果。HTD1801是全球首创的靶向AMPK-NLRP3通路的抗炎代谢调节剂（AIMM）。在已完成的III期临床研究（SYMPHONY-1&2）中，HTD1801显著改善了基线eGFR为60–90 mL/min/1.73m²的2型糖尿病（T2DM）患者的肾功能。治疗52周后，这些患者的eGFR平均升高了+3.08 mL/min/1.73m²（95% CI: 0.46–5.70），且未出现高滤过或体液潴留。这些结果提示，HTD1801和现有机制药物有差异化优势，并具有延缓甚至逆转疾病进程的潜力。本项研究进一步解释了上述临床结果。该研究由君圣泰医药与中国医学科学院医药生物技术研究所蒋建东院士研究团队共同完成，结果显示，在葡萄糖及棕榈酸诱导的足细胞损伤模型中，HTD1801可显著提升足细胞存活率、抑制细胞凋亡；恢复足细胞关键结构蛋白nephrin与podocin的表达；并显著降低代谢性炎症通路中磷酸化NF-κB及凋亡执行蛋白caspase-3水平。在糖尿病肾病（DN）模型中，HTD1801可呈剂量依赖性改善肾脏组织结构，降低肾小管损伤评分，减轻肾脏炎症及纤维化病变，并显著降低24小时尿微量白蛋白水平。该研究系统性阐明HTD1801可抑制足细胞炎症与凋亡、稳定肾小球结构，进一步揭示了HTD1801的肾脏保护潜力，为其成为慢性肾病（CKD）及其他肾脏疾病的潜在疗法提供了重要的科学依据。摘要标题：HTD1801减轻足细胞凋亡与肾小球损伤--肾脏保护机理探析报告编号：2243报告时间：2026年6月4日，星期四，上午8:15（英国夏令时间）报告形式：口头报告报告人：Filip Surmont博士，君圣泰医药首席医学官君圣泰医药首席医学官Filip Surmont博士表示："此次研究首次从足细胞与肾小球层面揭示了HTD1801的肾脏保护作用。临床研究与临床前研究结果的高度一致，进一步证实了HTD1801在CKD或其他肾脏疾病中直击核心病理进程的能力，彰显了其重要治疗潜力。我们将持续推进HTD1801在CKD等适应症的临床开发，力求为全球肾病患者带来更多创新的治疗选择。"关于HTD1801HTD1801是一款全球首创的新分子实体，旨在解决心肾代谢系统疾病（CKM）的未满足临床需求。HTD1801作为单一分子，是具有独特双机制的口服抗炎及代谢调节剂（AIMM），通过激活AMPK及抑制NLRP3炎症小体发挥其生物学活性；这种互补协同的双机制作用可有效解决代谢问题。全球多项临床结果验证HTD1801具有"一药多效"的特性，能够为患者带来综合获益，包括改善胰岛素敏感性、血糖控制、血脂降低、肾脏保护、体重减轻、肝脏获益及抗炎等。基于此，HTD1801有潜力成为CKM领域的基础性治疗药物。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ashley
ONERHT Foundation Raises Over S$280,000 for Local Charities and Announces New Leadership at 11th Anniversary Charity Golf & Gala Dinner
ONERHT Foundation Raises Over S$280,000 for Local Charities and Announces New Leadership at 11th Anniversary Charity Golf & Gala Dinner

SINGAPORE, June 5, 2026 - (ACN Newswire via SeaPRwire.com) - ONERHT Foundation Ltd (“Foundation”), the corporate social responsibility vehicle of RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) celebrated its 11th anniversary by hosting the annual Charity Golf & Gala Dinner at Sentosa Golf Club on 28 May 2026.The event, graced by Guest of Honour Mr Masagos Zulkifli, Minister for Social and Family Development, drew over 120 golfers from Singapore’s legal and professional community for a day of sports and philanthropy, culminating in a gala dinner that reaffirmed the Foundation’s enduring commitment to make a difference in the lives of those it serves. The event also marked the 15th anniversary of RHTLaw Asia LLP.The Foundation raised more than S$280,000 through the event to benefit four local charities, namely PCF Sparkle Care, Singapore Road Safety Council, Singapore Golf Association, and Bethel Community Services.In addition to the fundraising milestone, the evening saw a leadership transition within the Foundation. Ms Kaylee Kwok stepped down as Chairman with effect from 28 May 2026, having stewarded the Foundation through 4 years of sustained growth and deepening community impact.“It has been a great privilege to serve as Chairman of ONERHT Foundation. What began as a conviction that the legal and professional community could do more has grown into something truly meaningful, with over S$6 million raised, more than 40 beneficiaries supported, and countless lives touched across Singapore and the region. I am deeply grateful to our sponsors, donors, partners and our ONERHT colleagues for their strong support and commitment. I leave with full confidence that the Foundation’s best years are still ahead,” said Ms Kaylee Kwok.Mr Nandakumar Renganathan has been appointed as the new Chairman of ONERHT Foundation, also with effect from 28 May 2026. Mr Nandakumar brings with him a deep commitment to the Foundation’s mission and vision to extend its reach across Singapore and the broader ASEAN region.“I am deeply honoured to take on this role and equally grateful to Kaylee for her leadership and contributions to the Foundation. ONERHT Foundation stands for something bigger than any one of us, a belief that those of us in the legal and professional community have a responsibility to give back, not just once, but consistently and with purpose. I look forward to working with our sponsors, donors, partners and beneficiaries as well as our ONERHT colleagues to carry that mission forward and extend our reach even further across Singapore and ASEAN,” said Mr Nandakumar.The evening also witnessed the signing of a Memorandum of Understanding (MOU) between RHTLaw Asia and the Association for Persons with Special Needs (APSN), marking a new chapter in the Foundation’s commitment to building meaningful and lasting partnerships with the communities it serves.                                 ONERHT Foundation LtdA Singapore registered charity and grant-making philanthropic organisation, ONERHT Foundation Ltd (“Foundation”) enables RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) to do right and do good through various charitable endeavours. Set up by ONERHT in 2015, the Foundation was registered as a Singapore charity by the Commissioner of Charities and a grant-making philanthropic organisation by the Inland Revenue Authority of Singapore on 16 September 2016 and 28 November 2016 respectively.The Foundation seeks to establish, inspire and encourage the right philanthropic culture among the corporate and legal fraternity of giving back to the community in a focused, hands-on and meaningful manner. Since its inception, the Foundation has raised more than S$6 million to support more than 40 beneficiaries involved in education, environmental protection and sustainability, disadvantaged groups as well as the arts and sports.For more information, please visit www.onerht.foundationFor media enquiries, please contact:Melody OngEmail: melody@waterbrooks.com.sg+65 8901 9780General enquiries:Email: query@waterbrooks.com.sg+65 9338 8166 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

brooke
龙丰首日上市：定价吸引 基本面扎实具关注价值

香港, 2026年6月5日 - (亚太商讯 via SeaPRwire.com) - 龙丰（2290）今日（6月5日）正式于港交所挂牌上市，成功踏入国际资本市场。公司公开发售部分获得13.4万人认购，超购超过660倍，足证龙丰受到市场欢迎。公司最终定价为5.18港元，上市后市值约25.9亿元，公司预估2026财年全年纯利约2.65亿港元，即2026年预测市盈率9.8倍，相对同业莎莎（00178）目前动态市盈率超过20倍，龙丰上市定价极具吸引力。加上，公司亦承诺上市后每年建议分派的股息将不低于可供分配溢利的50%，以上市定价计，即2026年预测息率近5厘，此举不仅彰显其成长性，同时亦为投资者提供稳定的回报预期，相信会得到投资者追捧。复合年增长率达50%，业绩增长强劲龙丰近年表现出明显的高增长特征。2023至2025财年总收入由约10.94亿港元上升至24.61亿港元，复合年增长率达50%。2026财年首八个月收入约20.35亿港元，同比增长34.7%，纯利则大幅上升85.8%至约1.48亿港元，并预估全财年纯利将达约2.65亿港元。值得关注的是，龙丰并非单纯依靠开店推动收入，而是收入与盈利同步提升，反映其经营质素持续改善。毛利率由2023财年的24.9%提升至2025财年的31.6%，显示供应链优化及产品结构升级正在转化为实际盈利，这种增长结构在零售板块中相对具吸引力。供应链优势突出，构成长期竞争壁垒龙丰的核心优势在于其对供应链的深度掌控。集团采用“全球直采＋长期合作”模式，与超过600家供货商建立稳固合作关系，覆盖日本、韩国及欧美等市场。这不仅提升产品稳定性，更巩固其议价能力及货源优势。在此基础上，公司可持续优化产品结构并提升毛利率，同时配合自有品牌发展，目前已建立逾40个品牌，提供超过700款产品。供应链与品牌结合，使龙丰由单一零售渠道逐步转向具备品牌延展能力的平台型零售商，为长远发展提供支撑。“多品类＋大店”模式，提升消费与盈利能力从业务模型来看，龙丰采用“大店型＋多品类”策略。每间门店一般提供超过9,000个SKU，覆盖医药、保健及美妆等11大品类。该模式有助提升顾客停留时间及客单价，同时促进交叉销售，带来更高的营运效率。此外，门店布局覆盖核心旅游区与民生地区，形成“旅客消费＋本地需求”的双重客源结构。这不仅可受惠旅客回流带来的增量需求，亦具备稳定消费基础，使整体业务在不同周期下仍能维持相对稳定表现。门店高效复制，扩张确定性较强龙丰的门店模型亦具备高效率特点。据招股书披露，新店平均仅需3个月内即达至收支平衡，2至8个月内回本，这反映其在选址、营运及成本控制方面具备成熟能力。对投资者而言，短回本周期意味着资本投入风险较低，亦有助加快资金周转。该高复制性模式为未来开店提供稳定基础，使其扩张策略具备较高确定性，而非单纯依赖市场环境或短期需求拉动。扩张与派息并行，兼具增长与回报属性龙丰计划自上市起未来三个财年增设18至21间新店，以扩大网络覆盖。同时，公司将持续强化供应链及系统建设，并推动数码化与线上线下融合发展，为未来收入及盈利增长提供支持。龙丰具备高增长、高盈利能力、供应链优势及清晰派息政策等多项特点，在港股零售板块中属质素较为突出的标的。同时，上市定价处于区间较低水平，反映其在吸引投资者参与和兼顾长线表现之间作出平衡。在基本面支撑下，若公司能持续兑现业绩增长及扩张策略，预期将持续吸引市场关注，具备中长线跟踪价值。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ashley
SnowValley Secures New Partnerships Across Major Global Food Exhibitions in H1 2026, Steadily Expanding Its International Business
SnowValley Secures New Partnerships Across Major Global Food Exhibitions in H1 2026, Steadily Expanding Its International Business

Zhangjiakou, China, June 4, 2026 - (ACN Newswire via SeaPRwire.com) - In the first half of 2026, SnowValley, China's leading frozen potato product manufacturer, showcased its products and solutions at 4 of the world's premier food industry events — Gulfood in the Middle East, FOODEX Japan, FHA Food & Beverage in Singapore, and THAIFEX-Anuga Asia in Thailand. Through its presence at these flagship exhibitions, SnowValley further strengthened its reach across key consumer markets in the Middle East, East Asia, and Southeast Asia.Leveraging these world's top food industry exhibitions, SnowValley showcased its integrated industrial chain competitiveness and global service capabilities, attracting widespread attention from industry professionals, international buyers, and leading media worldwide.Recognized for multiple consecutive years among the Top 500 Chinese Brands and Top 500 Asian Brands, SnowValley continues to strengthen its international brand presence through its localized market strategies and deep engagement with overseas distribution networks across multiple countries. By securing a series of cross-border strategic partnerships, the company is further expanding its worldwide network and reinforcing its position in the global frozen potato products industry.Throughout the exhibitions, SnowValley earned strong recognition and trust from global buyers by leveraging its highly standardized manufacturing system, market-driven product customization capabilities, and efficient & reliable global supply chain. Today, SnowValley offers a portfolio of more than 160 SKUs, with products exported to over 40 countries and regions worldwide.With years of dedication to the potato products industry, SnowValley has achieved an all-round internationalization upgrade spanning product exports, brand development, and industry-standard promotion, driven by quality and innovation as the core and supported by global operations.Looking ahead, SnowValley will continue to enhance its product R&D capabilities and expand its international presence. By delivering high-quality deep-processed potato products, SnowValley  aims to empower the development of the global foodservice industry, promote the standardization and upgrading of the sector through leading quality, and continuously explore and create sustainable value within the global food supply chain.Company: SnowValley Food Hebei Co.,Ltd.Contact Person: Joyce YangEmail: sales@snowvalleyfood.comWebsite: https://snowvalleyfood.com/en/Telephone: +86 131 6429 9552City: Zhangjiakou, Hebei Province Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

brooke
Using Personal Loans Wisely to Improve Your Money Situation in Singapore
Using Personal Loans Wisely to Improve Your Money Situation in Singapore

SINGAPORE, June 4, 2026 - (ACN Newswire via SeaPRwire.com) - Managing money in a high-cost city like Singapore can feel complex, especially when multiple financial commitments run in parallel. From education expenses and medical bills to consolidating existing dues, Personal Loans in Singapore are often explored as a flexible financing option. When approached thoughtfully, they can help create breathing room in monthly cash flow and bring more structure to scattered payments. The key lies in understanding how these loans work in the local context and using them in ways that align with income patterns, interest rates, and realistic repayment timelines.Understanding how Personal Loans work in SingaporePersonal Loans in Singapore are unsecured loans, meaning they do not require collateral such as property or fixed deposits. Loan amounts can vary widely depending on income eligibility and lender criteria, subject to applicable regulatory requirements. Interest rates are often quoted as flat rates or effective interest rates (EIR), with EIRs commonly ranging between 2.65% and 3.75% per annum for salaried individuals. Understanding the difference between flat rates and EIRs, as well as how rates vary across lenders, can help borrowers estimate the actual cost of borrowing more accurately. Repayment tenures usually span from one to five years, offering flexibility to match monthly obligations with income cycles.Situations where Personal Loans may help improve cash flowPersonal Loans may be useful in specific scenarios where timing and predictability matter more than long-term borrowing. For instance, consolidating multiple high-interest payments into one structured loan can simplify finances and make monthly outflows easier to track. A consolidated single personal loan instalment per month may feel more manageable than juggling three or four smaller payments with varying due dates. Similarly, planned expenses such as professional certifications or home repairs may benefit from fixed monthly repayments rather than ad-hoc withdrawals from savings. This approach can help maintain liquidity while spreading costs over time.Using Personal Loans for Debt ConsolidationDebt consolidation is one of the more common reasons borrowers explore personal loans in Singapore, especially when dealing with credit card balances. For illustration purpose, credit cards may carry interest rates exceeding 25% per annum, which may strain monthly budgets if balances revolve. A Personal Loan with a materially lower EIR may help reduce the interest burden while providing a clear repayment end date. Over a three-year tenure, consolidating SGD 20,000 in outstanding balances may translate into more predictable instalments and less uncertainty around interest accumulation, depending on the applicable terms. This structured approach may help improve financial clarity without relying on short-term credit cycles.Practical tips to use Personal Loans thoughtfullyAlign the loan amount with a clear purposeBorrowing with a defined goal can help keep loan usage focused and intentional. Whether the aim is consolidating debt or funding a necessary expense, having a specific number in mind can prevent over-borrowing. In Singapore, lenders may offer higher limits based on income, but choosing only what is required can help keep monthly instalments comfortable. This approach may also reduce total interest paid over the loan tenure.Compare EIR, not just headline offersAdvertised rates can sometimes appear attractive, but the EIR provides a clearer picture of the total cost. Processing fees, early repayment charges, and administrative costs can influence the final amount paid. For example, a loan with a 3% flat rate can translate to an EIR closer to 5.5% once fees are factored in. Comparing EIRs across lenders can help identify options that fit better within monthly budgets.Choose a tenure that balances flexibility and affordabilityLonger tenures reduce monthly instalment amounts, but they also increase total interest paid. Shorter tenures may feel heavier on cash flow but can close the loan faster. Borrowers earning between SGD 4,000 and SGD 6,000 per month often opt for a two- to three-year tenure, as it balances instalment size with interest impact. Selecting a tenure that aligns with income stability can help maintain consistency in repayments.Understanding income-based borrowing limitsIn Singapore, borrowing limits for personal loans are typically tied to annual income levels and overall credit assessment. Individuals earning less than SGD 20,000 annually are generally subject to more restrictive unsecured credit caps, while those earning above SGD 30,000 may be eligible for higher unsecured credit limits, subject to the banks' internal credit assessments and applicable regulatory requirements. These guidelines are designed to encourage responsible borrowing without overextending financial capacity. Staying within these limits can help ensure that loan repayments remain proportionate to income, leaving room for savings and everyday expenses. This balance can support longer-term financial resilience rather than short-term relief.Building a healthier money outlook with structured repaymentsOne often overlooked benefit of personal loans is the predictability they bring to monthly planning. Fixed instalments can make it easier to map expenses, set aside savings, and track progress over time. Seeing a loan balance reduce each month steadily may also encourage better financial habits. In Singapore's fast-paced environment, this structure may help individuals stay focused on broader money goals while managing immediate needs. Over time, this clarity may contribute to improved confidence in handling finances.Making Personal Loans work for your financial contextUsing personal loans thoughtfully in Singapore can be a practical way to bring order to complex financial situations. When loan amounts, interest rates, and tenures are aligned with income and clear objectives, they can help improve cash flow and reduce financial stress. Rather than acting as a quick fix, personal loans can serve as a structured tool that supports better financial management. With careful comparison and realistic planning, they may fit into a broader strategy aimed at stability and long-term financial well-being.Disclaimer: This content is published by iQuanti Singapore Pte Ltd, an external marketer engaged and compensated by UOB LtdContact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

brooke
云顶新耀与天广实达成倍捷欣(R)商业化授权许可协议 深化亚太创新药市场布局
云顶新耀与天广实达成倍捷欣(R)商业化授权许可协议 深化亚太创新药市场布局

香港, 2026年6月4日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（HKEX 1952.HK）宣布与北京天广实生物技术股份有限公司（以下简称"天广实"）达成商业化授权许可合作协议，获得倍捷欣(R)（MIL62，通用名：奥妥珠单抗β注射液）在亚太地区（东南亚、印度、韩国、澳大利亚、新西兰、中国香港、中国澳门及中国台湾地区）的临床开发及商业化权益。根据相关协议，云顶新耀将向天广实支付人民币2,300万元的首付款，以及最高不超过人民币1.86亿元的销售里程碑款。天广实可获得该产品在亚太地区的销售毛利额分成款项。此次合作将进一步强化云顶新耀在肾科及自身免疫疾病等领域的亚太市场布局，并与现有肾科管线形成协同效应。云顶新耀将依托已获验证的临床开发及商业化能力，加速推动倍捷欣(R)的市场准入与商业化进程，持续释放亚太区域的增长潜力，并推进公司在全球创新药市场的长期战略发展。倍捷欣(R)是天广实自主研发的创新型第三代CD20抗体药物。根据相关资料显示，该药物已于2026年2月在中国获批上市，用于治疗视神经脊髓炎谱系疾病（NMOSD），成为全球首款治疗该疾病的CD20抗体，也是中国在该领域的首款国产药物。倍捷欣(R)用于治疗原发性膜性肾病（PMN）的新药上市申请亦处于中国国家药监局的"优先审评审批"阶段，有望成为全球首款获批的PMN特效药物。此外，倍捷欣(R)正在进行的临床III期试验覆盖系统性红斑狼疮（SLE）以及滤泡性淋巴瘤（FL）多个治疗领域，并具备向其他自身免疫性疾病持续拓展的潜力。云顶新耀董事会主席吴以芳表示："我们非常高兴能与天广实就倍捷欣(R)达成此次合作。倍捷欣(R)不仅是全球首款获批治疗NMOSD的CD20抗体，也是一款具有差异化优势和广阔市场前景的创新药，在肾科及自身免疫疾病领域展现出显著的临床潜力。此次合作将进一步丰富云顶新耀在肾科及自身免疫领域的产品布局，并与现有管线形成良好的协同效应。依托公司已建立并持续强化的临床开发及商业化能力，我们有信心加速推进倍捷欣(R)在亚太地区的开发与商业化进程，推动其尽快惠及更多患者，让创新疗法更快转化为临床可及性，并进一步提升公司在亚太及全球创新药市场的影响力。"天广实总裁陈鲁宁表示："我们非常欣喜与云顶新耀达成倍捷欣(R)在亚太地区的合作。倍捷欣(R)作为全球首款获批治疗NMOSD的CD20靶向药物，也是潜在全球首款治疗PMN的特效药物，拥有非常出色的产品竞争力与市场潜力。自产品上市以来，倍捷欣(R)在中国大陆地区已经取得了优异的商业化成绩，此次合作将进一步强化倍捷欣(R)在整个亚太市场的商业化网络与品牌影响力，为中国大陆以外的更多肾科及自身免疫性疾病患者带来「欣」希望。"倍捷欣(R)目前已在肾科及多个自身免疫疾病领域展现出显著的临床及治疗价值，并具备广阔的适应症拓展潜力。其在NMOSD、PMN及SLE等疾病领域的持续布局与进展，有望为患者带来更多创新治疗选择。NMOSD是一种高复发率、高致残率的中枢神经系统自身免疫性疾病，多发于青壮年女性。该病通常为急性或亚急性起病，可迅速进展，约90%的患者在三年内经历复发，严重者可导致失明甚至瘫痪。倍捷欣(R)在单药治疗中显示出降低复发风险的显著优势，并在疗效数据中展现出优异表现，凸显其作为单药疗法的临床价值与治疗便利性。PMN是成人肾病最常见的病理类型，约30%-40% 的患者在5-15年内可能进展为终末期肾病。目前全球范围内尚无获批的特效药。临床III期研究显示，倍捷欣(R)单药治疗在临床完全缓解、免疫学完全缓解及临床缓解等各项指标上均展现出显著优势。此外，倍捷欣(R)具有良好的安全性和耐受性，并且给药周期便捷，患者初始治疗后，每六个月仅需进行一次静脉注射，可显著降低治疗负担，同时有助于提升长期依从性。SLE是一种慢性系统性自身免疫疾病，倍捷欣(R)目前处于临床III期研究阶段，具有24–28周的长给药间隔优势，可满足患者对长效治疗方案的临床需求，有望为SLE患者提供更优治疗选择。此次合作被视为云顶新耀提升肾科及自身免疫领域战略纵深的重要举措。随着倍捷欣(R)在PMN等适应症上的开发与商业化推进，公司肾科产品矩阵将得到进一步补充，并强化现有管线的协同效应。此外，业内普遍认为，未来数年中国创新药加速进入亚太市场将迎来重要发展机遇。凭借临床价值、可负担性及可及性方面的综合优势，中国创新药与亚太地区日益增长的医疗需求持续契合。云顶新耀近年来持续推进亚太区域战略布局，已逐步形成覆盖临床开发、市场准入及商业化运营的能力体系。通过引入倍捷欣(R)等具备差异化临床价值的创新产品，云顶新耀正进一步拓展区域产品组合及市场覆盖，推动公司肾科及自身免疫领域商业化价值的释放，并为亚太业务发展注入新的增长动能。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ashley